NeoGenomics
 | |
| Company type | Public |
|---|---|
| Nasdaq: NEO S&P 600 Component Russell 2000 Component | |
| Industry | Biotechnology, Health care |
| Founded | 2002 |
| Headquarters | , United States |
Area served | Worldwide |
Key people | Chris Smith (Chairman and CEO) |
| Revenue | $500M |
Number of employees | 1600 (2019) |
| Website | neogenomics |
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is a high-complexity CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.[1]
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas.[2]
History
[edit]NeoGenomics first received state and national-level laboratory certifications in 2002. Three years later in 2005, the company developed a technical-only service model using FISH.
In 2013, the company launched its sequencing platform[3] and was listed on the Nasdaq Stock Market as NEO. In 2014, NeoGenomics launched molecular tests including BTK and CALR mutation analysis.[4][5]
In 2015, NeoGenomics acquired Clarient, Inc. and its subsidiary company, Clarient Diagnostic Services, Inc. , a national cancer diagnostics laboratory with capabilities in immunohistochemistry for solid tumor cancers from GE Healthcare.[6][7] Clarient is headquartered in Aliso Viejo, California; with an ancillary laboratory in Houston, Texas.[8]
In November 2017, NeoGenomics established their first headquarters outside the United States in Rolle, Switzerland.[9]
References
[edit]- ^ "Standardizing Biomarker Analysis Across Clinical Testing". Technology Networks. Retrieved 8 October 2017.
- ^ Hogan, Dick. "Fort Myers company buys cancer test provider for $275M". The News-Press. Retrieved 8 October 2017.
- ^ Mansell, Peter (19 November 2013). "Covance, NeoGenomics ally on CT testing services". PharmaTimes. Retrieved 8 October 2017.
- ^ "NeoGenomics Launches Two New Cancer Tests". FDAnews. Retrieved 8 October 2017.
- ^ "Lee-based NeoGenomics cancer research company acquires California lab". Naples Daily News. Retrieved 8 October 2017.
- ^ Wasserman, Robert (6 July 2016). "NeoGenomics deal with GE's Clarient 6 months later: boom or bust?". TheStreet. Retrieved 8 October 2017.
- ^ Stynes, Tess (21 October 2015). "NeoGenomics to Acquire GE Cancer Testing Unit Clarient". Wall Street Journal. Retrieved 8 October 2017.
- ^ Lawrence, Stacy. "Small cap NeoGenomics to buy GE cancer diagnostics biz Clarient for $300M". FierceBiotech. Retrieved 8 October 2017.
- ^ Nikolic, Dejan. "L'américain NeoGenomics installe son siège européen à Rolle". Le Temps (in French). Retrieved 8 October 2017.
